LATEST INSIGHTS

Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera

Mark Kelly, chief executive of advisory firm MKI Global Partners, said the deal had become “very political” and the structure was a sign that Novo had “no confidence itself in getting antitrust approvals done anywhere near as smoothly as Pfizer would”

Published by and image courtesy of Financial Times

Other Articles

Speak to us

Understanding how situations may evolve often requires a broader perspective than conventional market analysis alone.